|
| Human GPRC5D Protein-VLP (LTP10647) |
|
| LTP10647 |
|
| 100ug |
|
|
$1576 In stock |
| Chimeric antigen receptor (CAR) T cells, a type of cell-based immunotherapy, have shown some promising results in multiple myeloma, a bone marrow cancer. The orphan G protein–coupled receptor, class C group 5 member D (GPRC5D), normally expressed only in the hair follicle; using quantitative immunofluorescence, we determined that GPRC5D protein is expressed on CD138 MM cells from primary marrow samples with a distribution that was similar to, but independent of, BCMA. |
| Recombinant Human GPRC5D Protein-VLP is expressed from Expi293. It contains Met1-Val345. |
|
| GPRC5D |
|
| Human |
|
| Q9NZD1-1 |
|
| Met1-Val345 |
|
| The target protein has a predicted MW of 39.6 kDa. |
|
| Immobilized Human GPRC5D VLP at 5ug/ml (100ul/Well) on the plate. The dose-response curve for Anti-GPRC5D Antibody, hFc Tag with the EC50 of 11.8ng/ml was determined by ELISA. See the testing image for details. |
|
| 0 |
|
| Expi293 |
|
| > 95% as determined by HPLC |
|
| Less than 1EU per ug by the LAL method. |
|
| Lyophilized from 0.22 um filtered solution in PBS (pH 7.4). Normally, 8% trehalose is added as a protectant before lyophilization. |
|
| Reconstituted protein stable at -80 C for 12 months, 4 C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
|
| Shipped at ambient temperature. |
|
| Centrifuge tubes before opening. Reconstituting to a concentration of more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water. |
|
|  |
